Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL

Sponsor
Ascentage Pharma Group Inc.
Study ID
NCT05147467
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • APG2575 — DRUG
    APG-2575 orally once daily at 600mg dose levels, every 28 days as a cycle.

Study Details

The purpose of this study is to assess the efficacy and safety of APG-2575 single agent in patients with relapsed/refractory CLL/SLL.

Key Dates

First listed
Dec 7, 2021
Start date
Dec 28, 2021
Status verified
Mar 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2027

Study Design

Enrollment
75 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: APG-2575 single agent in Relapse/Refractory CLL/SLL
    APG-2575 orally once daily at 600mg dose levels, every 28 days as a cycle.

Primary Outcome Measure

Objective Response Rate (ORR) [ Time Frame: Up to 9 months after the last subject enrolled. ]

Central Contacts

Find similar trials

Nationwide
Leukemia (other) trialsOncology trialsBlood cancer trials

Related Studies